XML 74 R63.htm IDEA: XBRL DOCUMENT v3.25.2
License and Collaboration Agreements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Mar. 01, 2024
Feb. 07, 2024
Jun. 30, 2025
Oct. 31, 2024
Sep. 30, 2019
Jun. 30, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Jun. 30, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Receivables from licensing and collaboration agreements     $ 76,868,000     $ 76,868,000     $ 76,868,000   $ 4,722,000  
Revenue           110,565,000 $ 2,168,000   227,198,000 $ 213,288,000    
Deferred revenue, current portion     10,540,000     10,540,000     10,540,000   14,604,000  
Deferred revenue, noncurrent     14,667,000     14,667,000     14,667,000   17,095,000  
Common Stock                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Shares issued               10,975,784        
License and Collaboration Agreement | BMS                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Upfront payment yet to be received                       $ 90,000,000
License and Collaboration Agreement | Navire Pharma, Inc | BMS                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Initial transaction price for the license and collaboration agreement                 90,000,000      
Allocation of transaction price for research and development                 19,800,000      
Allocation of transaction price to licenses                 70,200,000      
Revenue                   9,900,000    
Deferred revenue     0     0     0   0  
Alexion License Agreements | Eidos                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Upfront payment received       $ 3,000,000                
Receivables from licensing and collaboration agreements     1,000,000     1,000,000     1,000,000   600,000  
Deferred revenue     3,000,000     3,000,000     3,000,000      
Deferred revenue, current portion     1,000,000     1,000,000     1,000,000   3,000,000  
Deferred revenue, noncurrent     2,000,000     2,000,000     2,000,000      
Upfront nonrefundable payment received         $ 25,000,000              
Alexion License Agreements | License and Services Revenue                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Regulatory milestone payment receivable subject to achievement of regulator milestones     30,000,000     30,000,000     30,000,000      
Regulatory milestone payments received     30,000,000                  
Alexion License Agreements | License and Services Revenue | Eidos                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Revenue           31,000,000     32,000,000      
Alexion Agreements | Eidos                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Revenue         26,700,000              
Upfront nonrefundable payment received         $ 25,000,000              
Alexion Agreements | Eidos | Common Stock                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Shares issued         556,173              
Shares issued, price per share         $ 44.95              
Aggregate purchase price         $ 25,000,000              
Excess of purchase price over the value of common stock shares         $ 1,700,000              
Bayer Exclusive License Agreement | Eidos                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Notice period for termination of agreement 270 days                      
Initial transaction price for the license and collaboration agreement $ 135,000,000                      
Allocation of transaction price for research and development 4,500,000                      
Allocation of transaction price to licenses 130,500,000                      
Bayer Exclusive License Agreement | License and Services Revenue | Eidos                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Revenue           400,000 400,000   700,000 400,000    
Bayer Exclusive License Agreement | License Revenue | Eidos                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Revenue                 75,000,000      
Bayer Exclusive License Agreement | Seller Parties | Eidos                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Upfront payment received 135,000,000                      
Regulatory and sales milestone payments eligible to receive 150,000,000                      
Sales milestones payments receivable upon the achievement 450,000,000                      
Bayer Exclusive License Agreement | Seller Parties | EU Commission Regulatory | Eidos                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Regulatory and sales milestones $ 75,000,000                      
Bayer License Agreements | Eidos                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Receivables from licensing and collaboration agreements     3,900,000     3,900,000     3,900,000   0  
Deferred revenue     2,800,000     2,800,000     2,800,000   3,500,000  
Deferred revenue, current portion     1,000,000     1,000,000     1,000,000   1,300,000  
Deferred revenue, noncurrent     1,800,000     1,800,000     1,800,000   2,200,000  
Bayer License Agreements | License and Services Revenue | Eidos                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Revenue           2,600,000 400,000   78,600,000 130,900,000    
Bayer Commercial Supply Agreement and Bayer API Supply Agreement | License and Services Revenue | Eidos                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Revenue             0     0    
Kyowa Kirin Exclusive License | QED Therapeutics, Inc                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Upfront payment received             100,000,000     100,000,000    
Development and regulatory milestone payments yet to be received   $ 81,400,000                    
Notice period for termination of agreement   180 days                    
Initial transaction price for the license and collaboration agreement   $ 100,000,000                    
Allocation of transaction price for research and development   30,900,000                    
Allocation of transaction price to licenses   $ 69,100,000                    
Kyowa Kirin Exclusive License | License and Services Revenue | QED Therapeutics, Inc                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Revenue           3,500,000 1,300,000   5,800,000 2,900,000    
KKC License Agreements | QED Therapeutics, Inc                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Receivables from licensing and collaboration agreements     100,000     100,000     100,000   0  
Deferred revenue     19,400,000     19,400,000     19,400,000   25,200,000  
Deferred revenue, current portion     8,500,000     8,500,000     8,500,000   10,300,000  
Deferred revenue, noncurrent     $ 10,900,000     10,900,000     10,900,000   $ 14,900,000  
KKC License Agreements | License and Services Revenue | QED Therapeutics, Inc                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                        
Revenue           $ 4,000,000 $ 1,300,000   $ 6,700,000 $ 72,100,000